Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline.
[3H]dopamine release
conditioned avoidance response
dopaminergic activity enhancer effect
monoamine oxidase inhibition
rasagiline
rat striatum
selegiline
trace amine-associated receptor 1
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Aug 2023
28 Aug 2023
Historique:
received:
17
07
2023
revised:
22
08
2023
accepted:
23
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Selegiline and rasagiline are two selective monoamine oxidase B (MAO-B) inhibitors used in the treatment of Parkinson's disease. In their clinical application, however, differences in L-dopa-sparing potencies have been observed. The aim of this study was to find neurochemical and behavioral explanations for the antiparkinsonian effects of these drugs. We found that selegiline possesses a dopaminergic enhancer effect: it stimulated the electrically induced [
Identifiants
pubmed: 37686140
pii: ijms241713334
doi: 10.3390/ijms241713334
pmc: PMC10487936
pii:
doi:
Substances chimiques
Selegiline
2K1V7GP655
rasagiline
003N66TS6T
Dopamine
VTD58H1Z2X
Indans
0
Monoamine Oxidase
EC 1.4.3.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Interior
ID : TKP2021-EGA-25
Références
Clin Neuropharmacol. 2016 Sep-Oct;39(5):227-31
pubmed: 27438181
Biochem Pharmacol. 1985 Dec 1;34(23):4105-8
pubmed: 3933519
Int J Mol Sci. 2022 Aug 01;23(15):
pubmed: 35955676
Life Sci. 1996;58(23):2101-14
pubmed: 8649195
Acta Neurol Scand. 2019 Jul;140(1):23-31
pubmed: 30963543
J Neural Transm (Vienna). 2003 Nov;110(11):1241-55
pubmed: 14628189
Br J Clin Pharmacol. 2018 Sep;84(9):1917-1927
pubmed: 29847694
Pharmacol Rep. 2014 Jun;66(3):453-8
pubmed: 24905523
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8966-71
pubmed: 11459929
Arch Int Pharmacodyn Ther. 1992 Mar-Apr;316:5-29
pubmed: 1356324
Pharmacol Toxicol. 1998 Feb;82(2):57-66
pubmed: 9498233
Adv Neurol. 1999;80:495-9
pubmed: 10410762
J Neurochem. 1990 Sep;55(3):981-8
pubmed: 2117053
Arch Neurol. 2002 Dec;59(12):1937-43
pubmed: 12470183
Br J Pharmacol. 1984 Nov;83(3):741-9
pubmed: 6439273
Patient Prefer Adherence. 2011 Jan 20;5:57-64
pubmed: 21423589
J Neurochem. 1966 Aug;13(8):655-69
pubmed: 5950056
Nature. 1977 Jan 6;265(5589):80-1
pubmed: 834248
Mol Pharmacol. 2001 Dec;60(6):1181-8
pubmed: 11723224
Lancet. 1977 Feb 26;1(8009):439-43
pubmed: 65560
Pol J Pharmacol Pharm. 1979 Jul-Aug;31(4):297-307
pubmed: 523338
Int J Mol Sci. 2023 Jun 09;24(12):
pubmed: 37373081
Br J Pharmacol. 1999 Dec;128(8):1723-32
pubmed: 10588928
J Neurochem. 2011 Jan;116(2):164-76
pubmed: 21073468
Br J Pharmacol. 2001 Jan;132(2):500-6
pubmed: 11159700
Eur J Pharmacol. 1975 Nov;34(1):181-7
pubmed: 1241962
Life Sci. 2003 May 9;72(25):2915-21
pubmed: 12697274
Neuron. 1998 Oct;21(4):885-93
pubmed: 9808473
Lancet. 1982 Sep 25;2(8300):695-6
pubmed: 6126632
Bioorg Med Chem. 2001 May;9(5):1197-212
pubmed: 11377178
Adv Biochem Psychopharmacol. 1972;5:393-408
pubmed: 5066229
J Pharmacol Exp Ther. 1979 Feb;208(2):195-202
pubmed: 216794
Neurobiol Dis. 2022 Oct 15;173:105851
pubmed: 36007757
J Neural Transm Suppl. 1998;52:287-300
pubmed: 9564629
Pharmacol Ther. 2005 Jan;105(1):69-84
pubmed: 15626456
Geroscience. 2023 Jun 12;:
pubmed: 37306892
J Neurochem. 1992 Jul;59(1):48-54
pubmed: 1351932
Naunyn Schmiedebergs Arch Pharmacol. 1976;292(1):9-14
pubmed: 934359
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6
pubmed: 19892733
Int J Mol Sci. 2017 Mar 04;18(3):
pubmed: 28273839
J Biol Chem. 2000 Sep 8;275(36):27703-7
pubmed: 10970903
Pharmacol Ther. 2007 Dec;116(3):355-90
pubmed: 17888514